Adalimumab in severe and acute sciatica: A multicenter, randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2339-2346

  Genevay, Stéphane ^a   Viatte, Sebastien ^a   Finckh, Axel ^a   Zufferey, Pascal ^b   Balagué, Federico ^c   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Intercantonal Hospital of la Broye   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FOLLOW UP; HUMAN; ISCHIALGIA; LEG PAIN; LUMBAR DISK HERNIA; MALE; MULTICENTER STUDY; OSWESTRY DISABILITY INDEX; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SWITZERLAND; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DISKECTOMY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERVERTEBRAL DISK DISPLACEMENT; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SELECTION; SCIATICA; TREATMENT OUTCOME;

EID: 77955406876     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27499     Document Type: Article

References (35)

1. Younes M, Bejia I, Aguir Z, Letaief M, Hassen-Zrour S, Touzi M, et al. Prevalence and risk factors of disk-related sciatica in an urban population in Tunisia. Joint Bone Spine 2006;73:538-42.
2. Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 1993;18:1433-8. (Pubitemid 23270906)
3. Cherkin DC, Deyo RA, Street JH, Barlow W. Predicting poor outcomes for back pain seen in primary care using patients' own criteria. Spine 1996;21:2900-7. (Pubitemid 27024798)
4. Young IA, Hyman GS, Packia-Raj LN, Cole AJ. The use of lumbar epidural/transforaminal steroids for managing spinal disease. J Am Acad Orthop Surg 2007;15:228-38.
5. Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, et al. Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 2007;356:2245-56. (Pubitemid 46849155)
6. Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 1934;211:210-5.
7. Mulleman D, Mammou S, Griffoul I, Watier H, Goupille P. Pathophysiology of disk-related sciatica. I. Evidence supporting a chemical component. Joint Bone Spine 2006;73:151-8.
8. Goupille P, Mulleman D, Paintaud G, Watier H, Valat JP. Can sciatica induced by disc herniation be treated with tumor necrosis factor α blockade? [review]. Arthritis Rheum 2007;56:3887-95.
9. Genevay S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, et al. Elevated levels of tumor necrosis factor-α in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine 2008;33:2041-6.
10. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 2004;63:1120-3. (Pubitemid 39120364)
11. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, et al. Tumor necrosis factor-α monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003;28:750-3. (Pubitemid 36459288)
12. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy 1980;66:271-3. (Pubitemid 11234479)
13. Vogler D, Paillex R, Norberg M, de Goumoens P, Cabri J. Cross-cultural validation of the Oswestry disability index in French. Ann Readapt Med Phys 2008;51:379-85.
14. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231)
15. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
16. Luo X, Lynn George M, Kakouras I, Edwards CL, Pietrobon R, Richardson W, et al. Reliability, validity, and responsiveness of the short form 12-item survey (SF-12) in patients with back pain. Spine 2003;28:1739-45. (Pubitemid 36961086)
17. Weinstein JN, Tosteson TD, Lurie JD, Tosteson AN, Hanscom B, Skinner JS, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA 2006;296:2441-50.
18. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling. College Station, TX; Stata Press.
19. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol 2005;32:2250-6. (Pubitemid 41587877)
20. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008;33:90-4.
21. Briggs M, Closs JS. A descriptive study of the use of visual analogue scales and verbal rating scales for the assessment of postoperative pain in orthopedic patients. J Pain Symptom Manage 1999;18:438-46.
22. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
23. Creange A, Barlovatz-Meimon G, Gherardi RK. Cytokines and peripheral nerve disorders. Eur Cytokine Netw 1997;8:145-51.
24. Ozaktay AC, Cavanaugh JM, Asik I, DeLeo JA, Weinstein JN. Dorsal root sensitivity to interleukin-1β, interleukin-6 and tumor necrosis factor in rats. Eur Spine J 2002;11:467-75. (Pubitemid 35232017)
25. Olmarker K, Larsson K. Tumor necrosis factor α and nucleuspulposus-induced nerve root injury. Spine 1998;23:2538-44. (Pubitemid 29003527)
26. Olmarker K, Nutu M, Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-α inhibition. Spine 2003;28:1635-41.
27. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001;26:863-9. (Pubitemid 32373971)
28. Weiler C, Nerlich AG, Bachmeier BE, Boos N. Expression and distribution of tumor necrosis factor α in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine 2005;30:44-53. (Pubitemid 40209276)
29. Ahn SH, Cho YW, Ahn MW, Jang SH, Sohn YK, Kim HS. mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. Spine 2002;27:911-7.
30. Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimaki J, Paimela L, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 2004;29:2115-9. (Pubitemid 40353199)
31. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Jarvinen S, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine 2005;30:2724-8. (Pubitemid 43011031)
32. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C, et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006;31:2759-66. (Pubitemid 44772773)
33. Tubach F, Ravaud P, Giraudeau B. Managing osteoarthritis of the knee: conclusions about use of NSAIDs are misleading [letter]. BMJ 2005;330:672.
34. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J Rheumatol 2006;33:1075-81.
35. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.